Navigation Links
Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease

izing this unique platform. Two U.S. patents have been issued and several others are pending.

Corgenix' clinical collaborators for the new AtherOx data include Thomas P. Greco, MD, Department of Medicine of Saint Mary's Hospital and Yale University School of Medicine, and Eiji Matsuura, PhD, Associate Professor, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Products using the AtherOx technology have not been cleared by the U.S. Food and Drug Administration for in vitro diagnostic use in the United States. In all countries where the use of this product has not been cleared by local regulating agencies, products using this technology shall not be used for diagnostic use as the performance characteristics have not been established. Two AtherOx products are CE-marked.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for vascular diseases, immunology disorders, and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 52 diagnostic products through a global distribution. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Compan
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
2. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
7. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
8. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
9. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
10. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
11. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
Post Your Comments:
(Date:11/27/2008)...lymphoblastic leukemia relapse cases arise from a ... , MEMPHIS, Tenn., Nov. 27 /PRNewswire-USNewsw... Hospital have identified distinctive genetic chan...phoblastic leukemia (ALL) that cause relapse. The ...or ALL relapse in children and, ultimately, in adu...
(Date:11/26/2008)..., FRANKLIN, Mass., Nov. 26 /PRNewswire-FirstCall...announced today that it has received full approval...for its U.S. pivotal trial to study the effectiven...sociated therapy in the prevention of Contrast-Ind...proved PLC,s request to expand their investigation...
(Date:11/25/2008)...t expanding statin use broadly in wake of AHA-pres... JUPITER, a clinical trial suggest... of healthy patients with elevated CRP, should not...rding to a national poll directed at health profes...online poll conducted by medical news site MedPage...
(Date:11/25/2008)...-FirstCall/ -- Pharmacyclics, Inc.,(Nasdaq: PCY... a Phase 1,clinical trial with PCI-27483, the com...r VIIa inhibitor. The trial was conducted in sixte... and pharmacologic effect of,PCI-27483. A single ...ose,response in the International Normalized Rati...
Breaking Medicine Technology:St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Martek to Announce Third Quarter 2007 Results on September 5 2007 83 1Martek to Announce Third Quarter 2007 Results on September 5 2007 83 2Avitar Reports Third Quarter Financial Results for Fiscal 2007 80 1Avitar Reports Third Quarter Financial Results for Fiscal 2007 80 2Avitar Reports Third Quarter Financial Results for Fiscal 2007 80 3Avitar Reports Third Quarter Financial Results for Fiscal 2007 80 4AUDIO from Medialink and GlaxoSmithKline 3A Fiber Key in Managing Irritable Bowel Syndrome 28IBS 29 Symptoms 77 1Ranexa 28R 29 Added to New ACC AHA Guidelines on Unstable Angina Non ST Elevation Myocardial Infarction 28UA NSTEMI 29 74 1Ranexa 28R 29 Added to New ACC AHA Guidelines on Unstable Angina Non ST Elevation Myocardial Infarction 28UA NSTEMI 29 74 2
...if., April 11, 2007,/PRNewswire-FirstCall/ -- Rige...update on R788, which is currently in ongoing,Phas...pura (ITP),rheumatoid arthritis (RA) and lymphoma...tor that blocks the activation of mast cells,macr...atory,responses and tissue damage. , Rigel commenc...
...SS WIRE)--Apr 11, 2007 - A comparison of,the long-...ug,therapies combined with symptom management vers...(R) (glatiramer acetate,injection) was the most co...tting multiple sclerosis (RRMS). The study provide...t-effectiveness of,multiple sclerosis (MS) therapi...
Other Medicine Technology:Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 2Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 3Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,Rheumatoid Arthritis and Lymphoma 4First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 2First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 3First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 4First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 5First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 6
(Date:12/2/2008)...ies, the problem with the holidays is family. Eld...ow caregivers of aging parents can bring the joy o... , San Mateo, CA (PRWEB) ...f the holiday season is family, especially aging p...er Koch , founder of Encore Management , has a si...
(Date:12/2/2008)...rofit Launches Age-related Macular Degeneration Ca...ible Patients and Free Eye-Healthy Cookbooks , ...cember 2, 2008 -- "Do You See What I See?&quo...n as Age-related Macular Degeneration (AMD) the an...his…. a large black hole in the center of y...
(Date:12/2/2008)...nnounces that the SouthEast Alaska Regional Health...ed the Rhapsody™ Integration Engine to help ... pharmacy, laboratory and business programs commun...nectivity to statewide systems such as VacTrAK (th...S (an MIS and clinical documentation tool used by ...
(Date:12/2/2008)... Provides Online Resource and Fire Safety Tips for... Boston, MA (PRWEB) December 2, 2008 -...eete , actress, philanthropist and mother of four,... a few moments before the holiday rush to review f...eSmart.com. , , , , ,Home fires top the list of A...
Breaking Medicine News(10 mins):Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 2Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Liberty Mutual and Holly Robinson Peete Team Up to Remind Families to Be Fire Smart this Holiday Season with Tips on Fire Safety 2Health News:Liberty Mutual and Holly Robinson Peete Team Up to Remind Families to Be Fire Smart this Holiday Season with Tips on Fire Safety 3Health News:Liberty Mutual and Holly Robinson Peete Team Up to Remind Families to Be Fire Smart this Holiday Season with Tips on Fire Safety 4
...A.P.J. Abdul Kalam Friday called for taking advant...ostic tool and of tele-radiology to help the needy...s speaking during a visit to the digital radiology...f India Limited (ECIL), which is working towards p...
...eshs Gorakhpur District are grappling to fight aga...is , that has killed at least 30 children in the p... Department, B.R.D Medical College, said that the ...ived over 100 patients since January out of whom 3...
...ay we interviewed a doctor - Dr.Makani Hemadri, wh...rrent problems facing the doctor community at lar...of healthcare systems in the world. Apparently alm...onal Health Service of England. In the US, Middle-...
Healthcare in India is presently the cynosure of global attention. A country that churns the highest number of medical brains, is also recording excellence in healthcare services. It is no longer wis
Other Medicine News:Health News:Interview With a Surgeon Hidden Hero of the NHS 2Health News:Interview With a Surgeon Hidden Hero of the NHS 3Health News:Interview With a Surgeon Hidden Hero of the NHS 4Health News:Interview With a Surgeon Hidden Hero of the NHS 5Health News:Interview With a Surgeon Hidden Hero of the NHS 6Health News:Interview With a Surgeon Hidden Hero of the NHS 7Health News:Interview With a Surgeon Hidden Hero of the NHS 8Health News:Lets Care For Our Physicians A Salute to Them on Doctors Day! 2Health News:Lets Care For Our Physicians A Salute to Them on Doctors Day! 3
...ing test for determining the presence of clinical ...randed system is considered the manual standard, a...r system meets defined NCCLS/ICSH guidelines desig...alized systems are also available for pediatric ap...
DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading.
...acids and is variably N-glycosylated. The variatio...tes of between 43 and 56 kDa. Insulin-like growth ... high affinity but do not bind insulin. Of the six...terized at this time, IGFBP-3 has been shown to be...
For the detection and semi-quantitation of antibodies against the Scl-70 antigen in serum as an aid in the diagnosis of autoimmune disease. The test can be performed either manually or in conjunction
Medicine Products: